Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
11th Congress of the European Hematology Association
Non-Hodgkin’s Lymphoma: Building on the Evidence
Amsterdam, The Netherlands / June 15-18, 2006
Amsterdam - Non-Hodgkin’s lymphoma (NHL) encompasses a diverse group of malignancies, some of which are aggressive in nature, such as diffuse large B-cell lymphoma, as well as slower-growing indolent ones, such as follicular lymphoma....
42nd Annual Meeting of the American Society of Clinical Oncology
Treatment Strategies for B-cell Chronic Lymphocytic Leukemia
Atlanta, Georgia / June 2-6, 2006
Atlanta - Chlorambucil, cyclophosphamide and fludarabine are considered first-line therapies for B-cell chronic lymphocytic leukemia (B-CLL). The goal of treatment is complete remission, with no evidence of minimal residual disease (MRD)....
42nd Annual Meeting of the American Society of Clinical Oncology
Refining Targeted Strategies for the Treatment of Chronic and Acute Myeloid Leukemia
Atlanta, Georgia / June 2-6, 2006
Atlanta - Current Canadian recommendations indicate that imatinib should be initiated as first-line therapy for patients in chronic-phase chronic myeloid leukemia (CML). Despite the tyrosine kinase inhibitor’s (TKI’s) excellent activity in...
42nd Annual Meeting of the American Society of Clinical Oncology
Lymphoma Update: Reviewing Maintenance and Induction-phase Therapy
Atlanta, Georgia / June 2-6, 2006
Atlanta - Outcomes for patients with follicular lymphoma had changed very little over four decades of treatment until the emergence of chemoimmunotherapy. Studies presented here this year confirmed earlier findings that the anti-CD20...
10th Conference of the Canadian Blood and Marrow Transplant Group
CML Standard of Care: Reviewing the Updated Recommendations
Edmonton, Alberta / April 21-24, 2006
Edmonton - In patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), the tyrosine kinase inhibitior (TKI) imatinib has become the gold standard of therapy. Long-term results from IRIS (International Randomized Trial...
10th Biennial Meeting of the Canadian Blood and Marrow Transplant Group
Expanding Therapeutic Options for Chronic Myeloid Leukemia
Edmonton, Alberta / April 21-24, 2006
Edmonton - The arrival of imatinib as a targeted therapeutic option for chronic myeloid leukemia (CML) has been a highly encouraging development for the prognosis for this disease, and for patients who achieve a good early response to...
31st Annual Meeting Association des médecins hématologues et oncologues du Québec
New Prognostic and Therapeutic Opportunities in Chronic Lymphocytic Leukemia
Vaudreuil, Quebec / April 20-23, 2006
Vaudreuil - Once considered nearly exclusively an indolent disease of the elderly, chronic lymphocytic leukemia (CLL) is becoming more common in younger individuals. Aggressive therapy may be more desirable for patients in this age group....
2nd European Congress on Hematologic Malignancies
Improving Survival in Follicular Lymphoma
Barcelona, Spain / February 24-26, 2006
Barcelona - The natural history of follicular non-Hodgkin’s lymphoma (NHL) following initial therapy is characterized by repeated relapses of increasingly shorter duration leading ultimately to death from progressive disease. Several...